Cargando…

Detection of Pancreatic Cancer Biomarkers Using Mass Spectrometry

BACKGROUND: Pancreatic cancer is the fourth leading cause of cancer-related deaths. Therefore, in order to improve survival rates, the development of biomarkers for early diagnosis is crucial. Recently, diabetes has been associated with an increased risk of pancreatic cancer. The aims of this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Kiyoun, Ahn, Soohyun, Lim, Johan, Yoo, Byong Chul, Hwang, Jin-Hyeok, Jang, Woncheol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4285963/
https://www.ncbi.nlm.nih.gov/pubmed/25673969
http://dx.doi.org/10.4137/CIN.S16341
_version_ 1782351630114488320
author Kim, Kiyoun
Ahn, Soohyun
Lim, Johan
Yoo, Byong Chul
Hwang, Jin-Hyeok
Jang, Woncheol
author_facet Kim, Kiyoun
Ahn, Soohyun
Lim, Johan
Yoo, Byong Chul
Hwang, Jin-Hyeok
Jang, Woncheol
author_sort Kim, Kiyoun
collection PubMed
description BACKGROUND: Pancreatic cancer is the fourth leading cause of cancer-related deaths. Therefore, in order to improve survival rates, the development of biomarkers for early diagnosis is crucial. Recently, diabetes has been associated with an increased risk of pancreatic cancer. The aims of this study were to search for novel serum biomarkers that could be used for early diagnosis of pancreatic cancer and to identify whether diabetes was a risk factor for this disease. METHODS: Blood samples were collected from 25 patients with diabetes (control) and 93 patients with pancreatic cancer (including 53 patients with diabetes), and analyzed using matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF/MS). We performed preprocessing, and various classification methods with imputation were used to replace the missing values. To validate the selection of biomarkers identified in pancreatic cancer patients, we measured biomarker intensity in pancreatic cancer patients with diabetes following surgical resection and compared our results with those from control (diabetes-only) patients. RESULTS: By using various classification methods, we identified the commonly splitting protein peaks as m/z 1,465, 1,206, and 1,020. In the follow-up study, in which we assessed biomarkers in pancreatic cancer patients with diabetes after surgical resection, we found that the intensities of m/z at 1,465, 1,206, and 1,020 became comparable with those of diabetes-only patients.
format Online
Article
Text
id pubmed-4285963
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-42859632015-02-11 Detection of Pancreatic Cancer Biomarkers Using Mass Spectrometry Kim, Kiyoun Ahn, Soohyun Lim, Johan Yoo, Byong Chul Hwang, Jin-Hyeok Jang, Woncheol Cancer Inform Original Research BACKGROUND: Pancreatic cancer is the fourth leading cause of cancer-related deaths. Therefore, in order to improve survival rates, the development of biomarkers for early diagnosis is crucial. Recently, diabetes has been associated with an increased risk of pancreatic cancer. The aims of this study were to search for novel serum biomarkers that could be used for early diagnosis of pancreatic cancer and to identify whether diabetes was a risk factor for this disease. METHODS: Blood samples were collected from 25 patients with diabetes (control) and 93 patients with pancreatic cancer (including 53 patients with diabetes), and analyzed using matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF/MS). We performed preprocessing, and various classification methods with imputation were used to replace the missing values. To validate the selection of biomarkers identified in pancreatic cancer patients, we measured biomarker intensity in pancreatic cancer patients with diabetes following surgical resection and compared our results with those from control (diabetes-only) patients. RESULTS: By using various classification methods, we identified the commonly splitting protein peaks as m/z 1,465, 1,206, and 1,020. In the follow-up study, in which we assessed biomarkers in pancreatic cancer patients with diabetes after surgical resection, we found that the intensities of m/z at 1,465, 1,206, and 1,020 became comparable with those of diabetes-only patients. Libertas Academica 2015-01-06 /pmc/articles/PMC4285963/ /pubmed/25673969 http://dx.doi.org/10.4137/CIN.S16341 Text en © 2014 the author(s), publisher and licensee Libertas Academica Ltd. This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License.
spellingShingle Original Research
Kim, Kiyoun
Ahn, Soohyun
Lim, Johan
Yoo, Byong Chul
Hwang, Jin-Hyeok
Jang, Woncheol
Detection of Pancreatic Cancer Biomarkers Using Mass Spectrometry
title Detection of Pancreatic Cancer Biomarkers Using Mass Spectrometry
title_full Detection of Pancreatic Cancer Biomarkers Using Mass Spectrometry
title_fullStr Detection of Pancreatic Cancer Biomarkers Using Mass Spectrometry
title_full_unstemmed Detection of Pancreatic Cancer Biomarkers Using Mass Spectrometry
title_short Detection of Pancreatic Cancer Biomarkers Using Mass Spectrometry
title_sort detection of pancreatic cancer biomarkers using mass spectrometry
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4285963/
https://www.ncbi.nlm.nih.gov/pubmed/25673969
http://dx.doi.org/10.4137/CIN.S16341
work_keys_str_mv AT kimkiyoun detectionofpancreaticcancerbiomarkersusingmassspectrometry
AT ahnsoohyun detectionofpancreaticcancerbiomarkersusingmassspectrometry
AT limjohan detectionofpancreaticcancerbiomarkersusingmassspectrometry
AT yoobyongchul detectionofpancreaticcancerbiomarkersusingmassspectrometry
AT hwangjinhyeok detectionofpancreaticcancerbiomarkersusingmassspectrometry
AT jangwoncheol detectionofpancreaticcancerbiomarkersusingmassspectrometry